Nerandomilast for Interstitial Lung Disease

This trial explores whether a medication called nerandomilast can help children and teens with interstitial lung disease (ILD), a condition where the lungs become stiff and scarred, making breathing difficult. For children aged 6 to 17, the study compares nerandomilast to a placebo to determine if it improves lung function and overall health. Participants aged 2 to 5 will receive nerandomilast from the start. Children and teens who have experienced worsening ILD symptoms or need more oxygen to breathe might be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial requires that you stop taking certain medications, like other PDE4 inhibitors and pirfenidone, before joining. If you're on these, you'll need to stop them 30 days or 8 weeks before the trial, respectively.

Research shows that nerandomilast is generally well-tolerated by people with lung conditions. In studies with patients who have pulmonary fibrosis, nerandomilast proved safe, as most patients did not experience serious side effects. Additionally, the treatment was linked to a lower risk of death in these patients.

Nerandomilast is unique because it offers a new approach to treating interstitial lung disease, potentially distinguishing itself from traditional options like corticosteroids and immunosuppressants. Researchers are excited about Nerandomilast because it targets inflammation more precisely, which might reduce side effects associated with broader immune suppression. Additionally, this treatment is being tested in a wide age range, including very young children, which is promising for a condition that lacks tailored pediatric options.

Research has shown that nerandomilast can slow the progression of idiopathic pulmonary fibrosis, a serious lung disease. Studies have found that this treatment may reduce the risk of death for individuals with this condition. Early results from a trial on interstitial lung disease (ILD) suggest that nerandomilast could be a promising option for treating lung fibrosis, a component of ILD. Specifically, one study found that nerandomilast significantly slowed the decline in lung function in individuals with worsening pulmonary fibrosis. This trial examines nerandomilast in different age groups, including children and teenagers, to assess its potential benefits for those with ILD.¹⁴⁶⁷